

PN : EP 910575 A1 990428  
AN : EP 97927386 970619  
PR : JP 16179196 960621  
NO : WO 9748726  
DS : AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE  
MC : C07K- 07/23  
IC : C07K- 01:02, C07K- 01:06  
ET : METHOD FOR PRODUCING PEPTIDES  
FT : PROCEDE DE PRODUCTION DE PEPTIDES  
GT : VERFAHREN ZUR HERSTELLUNG VON PEPTIDEN  
PA : Takeda Chemical Industries, Ltd.  
IN : HATANAKA, Chitoshi  
IN : ABE, Yasuaki  
IN : YAMANO, Mitsuhsisa

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :		A1	(11) International Publication Number:	WO 97/48726
C07K 7/23, 1/02, 1/06			(43) International Publication Date: 24 December 1997 (24.12.97)	
(21) International Application Number:		PCT/JP97/02097		
(22) International Filing Date:		19 June 1997 (19.06.97)		
(30) Priority Data:		8/161791 21 June 1996 (21.06.96) JP		
(71) Applicant (for all designated States except US):		TAKEDA CHEMICAL INDUSTRIES, LTD. [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ki, Osaka-shi, Osaka 541 (JP).		
(72) Inventors; and				
(75) Inventors/Applicants (for US only):		HATANAKA, Chitoshi [JP/JP]; 3-C2-304, Takenodai, Nagaokakyo-shi, Kyoto 617 (JP). ABE, Yasuaki [JP/JP]; 1-6, Isoshi 3-chome, Takarazuka-shi, Hyogo 665 (JP). YAMANO, Mitsuhsisa [JP/JP]; 19-1, Taishicho, Kawachinagano-shi, Osaka 586 (JP).		
(74) Agents:		ASAHIKA, Tadao et al.; Osaka Plant of Takeda Chemical Industries, Ltd., 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532 (JP).		
<p>(54) Title: METHOD FOR PRODUCING PEPTIDES</p> <p>(57) Abstract</p> <p>A peptide of the formula (I): 5-oxo-Pro-R<sup>1</sup>-Trp-Ser-R<sup>2</sup>-R<sup>3</sup>-R<sup>4</sup>-Arg-Pro-R<sup>6</sup>, wherein R<sup>1</sup> represents His, Tyr, Trp or p-NH<sub>2</sub>-Phe, R<sup>2</sup> represents Tyr or Phe, R<sup>3</sup> represents an optionally substituted Gly or an optionally substituted <math>\alpha</math>-D-amino acid residue, R<sup>4</sup> represents Leu, Ile or Nle, R<sup>6</sup> represents (1) Gly-NH-R<sup>7</sup>, wherein R<sup>7</sup> represents a hydrogen atom or an alkyl group which may optionally be substituted with a hydroxyl group, or (2) NH-R<sup>8</sup>, wherein R<sup>8</sup> represents a hydrogen atom, an alkyl group which may optionally be substituted with a hydroxyl group or an ureido group (-NH-CO-NH<sub>2</sub>), is produced advantageously in an industrial scale by reacting a peptide of the formula (II): 5-oxo-Pro-R<sup>1</sup>-Trp-Ser-R<sup>2</sup>-R<sup>3</sup>-OH, wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> have the same meanings as defined above or its salts, with a peptide of the formula (III): H-R<sup>4</sup>-R<sup>5</sup>-Pro-R<sup>6</sup>, wherein R<sup>4</sup> and R<sup>6</sup> have the same meaning as defined above and R<sup>5</sup> represents Arg which has been protected or its salts, to produce a peptide of the formula (I'): 5-oxo-Pro-R<sup>1</sup>-Trp-Ser-R<sup>2</sup>-R<sup>3</sup>-R<sup>4</sup>-R<sup>5</sup>-Pro-R<sup>6</sup>, wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> have the same meanings as defined above or its salt, and then subjecting thus obtained peptide (I') to a de-protecting group reaction.</p>				
<p>(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>				

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## DESCRIPTION


## METHOD FOR PRODUCING PEPTIDES


5      Technical Field

This invention relates to a method for producing peptides, which have an activity of an agonist of luteinizing hormone releasing hormones (LHRH) secreted from the hypothalamus or their salts. The present 10 invention further relates to an intermediate peptide, its production method, its crystals and a method for producing the crystals.

Background Art

15      U.S. Patent No. 4,008,209 which corresponds to Japanese Patent Application Laid-open No. 50-059370/1975, describes the following method for producing a peptide of the formula: (Pyr)Glu-His-Trp-Ser-Tyr(or Phe)-X-Leu(or Ile, or Nle)-Arg-Pro-HH-R, 20 wherein each amino acid residue has L-configuration unless otherwise indicated; X represents D-Leu, D-NLe, D-NVa, D-Ser, D-Abu, D-Phg, D-Phe or  $\alpha$ -Aibu; R represents an alkyl group which may optionally have hydroxyl.





10 In the reaction scheme, all symbols have the same meanings as defined above.

Japanese Patent Application Laid-open No. 51-6926/1996, which corresponds to U.S. Patent No. 3,997,516, describes a method for producing a peptide having a guanidino group which comprises protecting the guanidino group of a guanidino group-containing peptide with a lower alkoxybenzenesulfonyl group or tri(lower)alkyl-benzenesulfonyl group.

Furthermore, Japanese Patent Application Laid-open No. 51-100030/1996, which corresponds to U.S. Patent No. 3,997,516, describes a method for producing a peptide having a guanidino group which comprises protecting the guanidino group of a guanidino group-containing peptide with a lower alkoxybenzenesulfonyl group or tri(lower)alkylbenzenesulfonyl group and, after the peptide condensation reaction, removing the protective group with a halogenosulfonic or lower alkylsulfonic acid or a Lewis acid.

For the production of a peptide on a commercial scale, it is essential that various parameters such as (1) qualities of starting materials, (2) production cost, (3) workability, (4) safety to operators, and (5) prevention of pollution should satisfy certain practically acceptable levels and every process that is satisfactory at the laboratory level is not necessarily satisfactory at the factory level. Therefore, design of a commercial process for producing a peptide involves many problems that must be solved for

satisfying a variety of requirements such as the modality of peptide chain extension; the selection of the site of fragment condensation; the method for inhibiting isomerization at condensation of fragments; 5 the selection of protective groups for the  $\alpha$ -position and side-chain functional groups; the method for final elimination of such protective groups; the method for purification of the end product peptide; and the overall operability of the series of steps, among 10 others.

Furthermore, a diversity of methods and a variety of reaction conditions may be contemplated for the synthesis of peptides in general but it is often the case that because of non-crystallizability, many 15 intermediates used in the process cannot be sufficiently purified or require time-consuming fractionation procedures, with the result that many processes are not satisfactory in the reproducibility of quality and yield. Thus, the physical 20 characteristics such as crystallizability, stability, and solubility of intermediates, which are key factors in the respective production stages, hold sway over whether a process can be commercially acceptable in many cases.

25 Referring to the methodology for production of the peptide of the formula:(Pyr)Glu-His-Trp-Ser-Tyr(or Phe)-X-Leu(or Ile, or Nle)-Arg-Pro-HH-R, the process disclosed in U.S. Patent No. 4,008,209, which corresponds to Japanese Patent Application Laid-open 30 No. 50-059370/1975, protects the guanidino group of Arg with nitro and, therefore, the group Z used for protecting the  $\alpha$ -amino group can hardly be reductively eliminated selectively, so that HBr-AcOH is used for removal of group Z. Inevitably, in this process, 35 benzyl bromide, which is highly lacrimetory, is by-produced in a large quantity and, moreover, a large

amount of ether must be used for isolation of the end product. In addition, while the end product of this reaction is usually recovered in the hydrobromide form, the hydrogen bromide must be removed with, for example, 5 an ion exchange resin in order that the objectionable isomerization or condensation of fragments may be inhibited. Furthermore, while the gradient elution method is used in the chromatographic purification of the final end product, the above peptide, the lower 10 reproducibility of the concentration gradient necessitates rigorous qualitative testing, with the result that the operation for steady production of the desired product of uniform quality cannot be stand-ardized. Therefore, the process is not suited for 15 industrial-scale production.

Furthermore, in the U.S. Patent 3,997,516, a reaction scheme produces a peptide of the formula: (Pyr)Glu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg(MBS)-Pro-NH-C<sub>2</sub>H<sub>5</sub>, 20 wherein MBS denotes p-methoxybenzenesulfonyl group. However, in the U.S. patent, only the reaction scheme is described, but other details such as reaction conditions are not described at all.

Thus, an industrially profitable process for 25 producing peptides which have an activity of an agonist of LHRH or its salts with safety, expedience, high yield and good reproducibility has been awaited.

The inventors of the present invention explored the above-mentioned problems with diligence and 30 succeeded in establishing a protocol for the effective production of intermediate peptide (II), mentioned below, through inhibition of isomerization of amino acid residues in the hydrolysis reaction step, a protocol for crystallization of the peptide (II); and 35 deprotection on an industrial scale of peptide (I'), mentioned below; and a protocol for industrial-scale

purification of the objective peptide (I), mentioned below. Accordingly, the inventors arrived at a process for producing said peptide (I) with safety, high yield, and good reproducibility, and have completed the  
5 present invention.

Disclosure of Invention

The present invention is directed to

(1) A method for producing a peptide of the formula:

10        5-oxo-Pro-R<sup>1</sup>-Trp-Ser-R<sup>2</sup>-R<sup>3</sup>-R<sup>4</sup>-Arg-Pro-R<sup>6</sup>            (I) (SEQ  
ID NO: 6)

wherein R<sup>1</sup> represents His, Tyr, Trp or p-NH<sub>2</sub>-Phe, R<sup>2</sup> represents Tyr or Phe, R<sup>3</sup> represents an optionally substituted Gly or an optionally substituted α-D-amino acid residue, R<sup>4</sup> represents Leu, Ile or Nle, R<sup>6</sup> represents (1) Gly-NH-R<sup>7</sup>, wherein R<sup>7</sup> represents a hydrogen atom or an alkyl group which may optionally be substituted with a hydroxyl group or (2) NH-R<sup>8</sup>, wherein R<sup>8</sup> represents a hydrogen atom, an alkyl group which may 15 optionally be substituted with a hydroxyl group or an ureido group (-NH-CO-NH<sub>2</sub>), or its salts, which comprises reacting a peptide of the formula:

5-oxo-Pro-R<sup>1</sup>-Trp-Ser-R<sup>2</sup>-R<sup>3</sup>-OH            (II) (SEQ ID NO: 4)

wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> have the same meanings as defined 20 above or its salts, with a peptide of the formula:

H-R<sup>4</sup>-R<sup>5</sup>-Pro-R<sup>6</sup>            (III)

wherein R<sup>4</sup> and R<sup>6</sup> have the same meaning as defined above and R<sup>5</sup> represents Arg which has been protected, or its salts, to produce a peptide of the formula:

30        5-oxo-Pro-R<sup>1</sup>-Trp-Ser-R<sup>2</sup>-R<sup>3</sup>-R<sup>4</sup>-R<sup>5</sup>-Pro-R<sup>6</sup> (I') (SEQ ID  
NO: 5)

wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> have the same meanings as defined above, or its salt, and then subjecting thus obtained peptide (I') to a de-protecting group  
35 reaction,

- (2) A method according to the item (1), wherein R<sup>1</sup> is His, R<sup>2</sup> is Tyr, R<sup>3</sup> is Gly, D-Leu, D-Trp, D-Val which may be substituted with C<sub>1-4</sub> alkyl, D-Ser, D-Ala which may be substituted with C<sub>1-4</sub> alkoxy, with naphthyl or  
5 with 2-methylindolyl, or D-His which may be substituted with C<sub>7-10</sub> aralkyl, R<sup>4</sup> is Leu, R<sup>5</sup> is Arg which is protected with a group selected from the group consisting of a C<sub>1-6</sub> alkoxybenzenesulfonyl group, tri-C<sub>1-6</sub> alkylbenzenesulfonyl group and a nitro group, R<sup>6</sup> is a  
10 group of the formula: NH-R<sup>8'</sup>, wherein R<sup>8'</sup> is a hydrogen atom or an alkyl group which may optionally be substituted with hydroxyl,
- (3) A method according to the item (1), wherein R<sup>1</sup> is His, R<sup>2</sup> is Tyr, R<sup>3</sup> is D-Leu, R<sup>4</sup> is Leu, R<sup>5</sup> is Arg which is protected with a C<sub>1-6</sub> alkoxybenzenesulfonyl group, R<sup>6</sup>  
15 is a group of the formula: NH-R<sup>8''</sup>, wherein R<sup>8''</sup> is a C<sub>1-3</sub> alkyl group which may optionally be substituted with hydroxyl,
- (4) A method according to the item (1), wherein the  
20 reaction of the peptide (II) or its salts with the peptide (III) or its salts is carried out at a temperature ranging from about 0 to 40°C for about 30 to 60 hours,
- (5) A method according to the item (1), wherein an  
25 acid is used in the de-protecting group reaction,
- (6) A method according to the item (5), wherein the acid is C<sub>1-6</sub> alkylsulfonic acid,
- (7) A method according to the item (5), wherein the acid is used at a ratio of about 5 to 25 times (weight)  
30 of the peptide (I'),
- (8) A method for recovering and purifying the peptide (I) as defined in the above item 1, which comprises subjecting the reaction mixture containing an emerged oily product of a free form to a purification of column chromatography, the reaction mixture being obtained by  
35

the reaction of de-protecting group reaction of the Peptide (I') under the existence of an acid and then neutralized with a base,

(9) A peptide of the formula:

5        5-oxo-Pro-R<sup>1</sup>-Trp-Ser-R<sup>2</sup>-R<sup>3</sup>-OR<sup>9</sup>        (IV) (SEQ ID NO: 3)

wherein R<sup>1</sup> is His, Tyr, Trp or p-NH<sub>2</sub>-Phe, R<sup>2</sup> is Tyr or Phe, R<sup>3</sup> is optionally substituted Gly or an optionally substituted  $\alpha$ -D-amino acid residue and R<sup>9</sup> is a protecting group, or its salt,

10      (10) A peptide according to the item (9), wherein R<sup>1</sup> is

His, R<sup>2</sup> is Tyr, R<sup>3</sup> is Gly, D-Leu, D-Trp, D-Val which may be substituted with C<sub>1-4</sub> alkyl, D-Ser, D-Ala which may be substituted with C<sub>1-4</sub> alkoxy, with naphthyl or with 2-methylindolyl, or D-His which may be substituted

15      with C<sub>7-10</sub> aralkyl, R<sup>9</sup> is C<sub>1-6</sub> alkyl, C<sub>6-10</sub> aryl or C<sub>7-12</sub> aralkyl, or its salt,

(11) A peptide according to the item (9), wherein R<sup>1</sup> is His, R<sup>2</sup> is Tyr, R<sup>3</sup> is D-Leu, R<sup>9</sup> is C<sub>1-6</sub> alkyl, or its salt,

20      (12) A method for producing a peptide of the formula:

5-oxo-Pro-R<sup>1</sup>-Trp-Ser-R<sup>2</sup>-R<sup>3</sup>-OH        (II) (SEQ ID NO: 4)

wherein R<sup>1</sup> is His, Tyr, Trp or p-NH<sub>2</sub>-Phe, R<sup>2</sup> is Tyr or Phe, R<sup>3</sup> is optionally substituted Gly or an optionally substituted  $\alpha$ -D-amino acid residue, or its salt, which comprises hydrolyzing a peptide of the formula:

5-oxo-Pro-R<sup>1</sup>-Trp-Ser-R<sup>2</sup>-R<sup>3</sup>-OR<sup>9</sup>        (IV) (SEQ ID NO: 3)

wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> have the same meanings as defined above, R<sup>9</sup> is a protecting group, or its salt,

(13) A crystal of a peptide of the formula:

30      5-oxo-Pro-R<sup>1</sup>-Trp-Ser-R<sup>2</sup>-R<sup>3</sup>-OH        (II) (SEQ ID NO: 4)

wherein R<sup>1</sup> is His, Tyr, Trp or p-NH<sub>2</sub>-Phe, R<sup>2</sup> is Tyr or Phe, R<sup>3</sup> is optionally substituted Gly or an optionally substituted  $\alpha$ -D-amino acid residue, or its salt,

(14) A method for producing a crystal of a peptide of  
35      the formula:

5-oxo-Pro-R<sup>1</sup>-Trp-Ser-R<sup>2</sup>-R<sup>3</sup>-OH (II) (SEQ ID NO:4)  
wherein R<sup>1</sup> is His, Tyr, Trp or p-NH<sub>2</sub>-Phe, R<sup>2</sup> is Tyr or Phe, R<sup>3</sup> is optionally substituted Gly or an optionally substituted α-D-amino acid residue, or its salt, which  
5 comprises subjecting a solution of the peptide (II) or its salt to aging, and  
(15) A method according to the item (14), wherein the solution of the peptide (II) or its salt with the concentration of about 0.01 to 0.05 mole/liter is  
10 subjected to aging at a temperature ranging from about 10 to 70°C for about 10 to 70 hours.

Brief Description of Drawings

15 Figure 1 is a typical flow chart showing a preferred process of the present invention.

Best Mode for Carrying Out the Invention

The meanings of the symbols and/or abbreviations are shown below:

20 R<sup>1</sup> denotes His, Tyr, Trp or p-NH<sub>2</sub>-Phe, and His is preferable.

R<sup>2</sup> denotes Tyr or Phe, and Tyr is preferable.

25 As α-D-amino acid residue in the optionally substituted α-D-amino acid residue, mention is made of D-Leu, D-Ile, D-Nle, D-Val, D-Nva, D-Ser, D-Abu, D-Phe, D-Phg, D-Thr, D-Met, D-Ala, D-Trp or α-Aibu. As the α-D-amino acid residue, D-Leu, D-Val, D-Ser, D-Trp, D-Ala, D-Abu and α-Aibu are preferable, and D-Leu is more preferable.

30 As the substituent on the Gly or α-D-amino acid residue, mention is made of (1) mono-C<sub>1-4</sub> alkyl, e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, (2) di C<sub>1-4</sub> alkyl, e.g. dimethyl, diethyl, (3) tri C<sub>1-4</sub> alkyl, e.g. trimethyl, triethyl, (4) C<sub>1-4</sub> alkoxy, e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-

butoxy, (5) C<sub>6-10</sub> aryl, e.g. phenyl, naphthyl, (6) C<sub>7-10</sub> aralkyl, e.g. benzyl, phenethyl, (7) indolyl, (8) methylindolyl and (9) benzylimidazolyl. Among others, methyl, dimethyl, trimethyl, t-butyl, t-butoxy, 2-naphthyl, indol-3-yl, 2-methylindolyl and benzylimidazol-2-yl. Especially, trimethyl, t-butyl, t-butoxy, 2-naphthyl, indol-3-yl, 2-methylindolyl and benzylimidazol-2-yl are more preferable.

As preferable example of R<sup>3</sup>, mention is made of Gly, D-Leu, D-Trp, D-Val which may be substituted with C<sub>1-4</sub> alkyl, D-Ser, D-Ala which may be substituted with C<sub>1-4</sub> alkoxy, with naphthyl or with 2-methylindolyl, or D-His which may be substituted with C<sub>7-10</sub> aralkyl.

As more preferable examples of R<sup>3</sup>, mention is made of Gly, D-Leu, D-Trp, 3-methyl-D-Val, D-Ser, t-butoxy-D-Ala, 2-naphthyl-D-Ala, 2-methylindolyl-D-Ala, benzylimidazol-2-yl-D-Ala (= N<sup>im</sup>-benzyl-D-His).

R<sup>4</sup> denotes Leu, Ile or Nle. As R<sup>4</sup>, Leu is preferable.

As the protecting group in the protected Arg of R<sup>5</sup>, mention is made of an alkoxybenzenesulfonyl group, a trialkylbenzenesulfonyl group.

The alkoxybenzenesulfonyl is preferably a C<sub>1-6</sub> alkoxy-substituted benzenesulfonyl group such as p-methoxybenzenesulfonyl, p-ethoxybenzenesulfonyl, p-isopropoxybenzenesulfonyl, etc. and more preferably is p-methoxybenzenesulfonyl.

The alkyl moieties in the trialkylbenzenesulfonyl group are preferably C<sub>1-6</sub> alkyl groups, same or different, such as methyl, ethyl, propyl, n-butyl, t-butyl, n-pentyl, t-pentyl, etc. The three alkyl groups may be present in optional substitutable positions on the benzene ring of benzenesulfonyl but are preferably situated in the 2-, 4-, and 6-positions with respect to the sulfonyl group. Specifically, 2,4,6-

trimethylbenzenesulfonyl, 2,4,6-  
triethylbenzenesulfonyl, 2,4,6-  
tripropylbenzenesulfonyl, 2,4,6-  
triisopropylbenzenesulfonyl, 2,4,6-tri-t-  
5 butylbenzenesulfonyl, etc. can be typically mentioned.

As more preferable examples of the protecting group in the protected Arg of R<sup>5</sup>, mention is made of C<sub>1-6</sub> alkoxybenzenesulfonyl group, more preferably p-methoxybenzenesulfonyl, p-ethoxybenzenesulfonyl, p-10 propoxybenzenesulfonyl, p-isopropoxybenzenesulfonyl, still more preferably p-methoxybenzenesulfonyl.

The alkyl group of the "alkyl which may optionally have hydroxyl" mentioned for the group R<sup>7</sup> and R<sup>8</sup> is a C<sub>1-4</sub> alkyl group such as methyl, ethyl, n-propyl, 15 isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, and is preferably ethyl, which may have hydroxyl in any substitutable position.

As preferable example of the alkyl which may optionally have hydroxyl, mention is made of 20 hydroxymethyl, 2-hydroxyethyl, 3-hydroxy-n-propyl, 4-hydroxy-n-butyl, etc., and 2-hydroxyethyl is still more preferable.

As the protecting group of R<sup>9</sup>, mention is made of C<sub>1-6</sub> alkyl, e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, n-hexyl, etc., C<sub>7-10</sub> aralkyl, e.g. benzyl, phenethyl, etc. The group R<sup>9</sup> is 25 preferably C<sub>1-3</sub> alkyl, more preferably ethyl.

Throughout this specification (and appended claims), amino acids and peptides are referred to by 30 the abbreviations according to IUPAC-IUB Commission on Biological Nomenclature or by the trivial names which are in routine use in the art. Where any amino acid may exist as optical isomers, the L-compound is meant unless otherwise indicated.

35 It should also be understood that the following

abbreviations, among others, are sometimes used in this specification.

	Gly	: glycine
	Ala	: alanine
5	Val	: valine
	Leu	: leucine
	Ile	: isoleucine
	Ser	: serine
	Thr	: threonine
10	Arg	: arginine
	Phe	: phenylalanine
	Tyr	: tyrosine
	His	: histidine
	Trp	: tryptophan
15	Pro	: proline
	NLe	: norleucine
	NVa	: norvaline
	Abu	: 2-aminobutyric acid
	Phg	: phenylglycine
20	$\alpha$ -Aibu	: $\alpha$ -aminoisobutyric acid
	P-NH <sub>2</sub> -Phe	: p-aminophenylalanine
	Z	: benzyloxycarbonyl
	Pd	: palladium
	Pd-C	: palladium-carbon
25	Et	: ethyl
	AcOH	: acetic acid
	HF	: hydrogen fluoride
	HBr	: hydrogen bromide
	DCHA	: dicyclohexylamine
30	DMF	: N,N-dimethylformamide
	DMA	: N,N-dimethylacetamide
	THF	: tetrahydrofuran
	MSA	: methanesulfonic acid
	MBS	: p-methoxybenzenesulfonyl
35	DCC	: N,N'-dicyclohexylcarbodiimide
	HONB	: N-hydroxy-5-norbornene-2,3-dicarboximide

HOSu : N-hydroxysuccinimide  
HOBt : 1-hydroxybenzotriazole  
EDA : ethyl-3-(3-dimethylamino)propylcarbodiimide  
hydrochloride

5 NP : p-nitrophenyl

HPLC : High performance liquid chromatography

Methods for the production of the peptide (I) are described below:

A variety of synthetic routes can be contemplated  
10 for the production of the peptide of the formula (I) or its salt and a diversity of combinations are available in regard to amino- and carboxy-protecting groups, methods for amide bond formation, methods for deprotection, and methods for purification of peptides  
15 obtained in the respective routes of synthesis.

Among such alternatives the synthetic route of Figure 1 is one of preferred examples. Thus, the production technology of the present invention comprises (1) protecting the guanidino group of Arg<sup>8</sup>  
20 with a protecting group, (2) synthesizing two key intermediate fragments, e.g. Peptide (II) and Peptide (III), and (3) de-protecting the precursor peptide (I'), which is available upon condensation of said peptides from the guanidino group of Arg<sup>8</sup> to provide  
25 the objective peptide (I) or salt thereof.

As the salt of the present peptide, mention is made of salts with an organic acid, e.g. formic acid, acetic acid, propionic acid, lactic acid, glucolic acid, pyroracemic acid, oxalic acid, malonic acid,  
30 succinic acid, maleic acid, fumaric acid, p-toluenesulfonic acid, trifluoroacetic acid, methanesulfonic acid, phosphoric acid, etc, an inorganic acid, e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, etc.

35 1. Method for producing Peptide (a):

The peptide of the formula (a), whose structure

being shown as Z-R<sup>2</sup>-R<sup>3</sup>-OR<sup>9</sup>, can be produced by a manner described in "Peptide Gousei-no-Kiso-to-Jikken" (Basis and Experiment of Peptide Synthesis), edited by Nobuo Izumiya et al., Maruzen Publishers, Japan; or "The Peptide", vol. 1, pages 76-136, Ebehard Schröder and Klaus Lübke, or in a similar manner thereto.

5        2. Method for producing Peptide (b) from Peptide (a):  
In the production process of the present  
invention, peptide (b), Z-Ser-R<sup>2</sup>-R<sup>3</sup>-OR<sup>9</sup> which is shown  
10      in Fig. 1, is synthesized by condensing the dipeptide  
(a) with Z-Ser.

15      At first, the peptide (a) is subjected to a  
reaction of elimination of the group Z to produce de-Z  
peptide (a) (peptide (a) minutes "Z" group). As the  
elimination reaction, catalytic reduction using a  
catalyst such as Pd, Pd-C, and HBr/AcOH treatment are  
preferable.

20      As the solvent in the catalytic reduction,  
alcohols, e.g. methanol, ethanol, isopropanol, n-  
propanol, n-butanol, t-butanol, etc, ethers, such as  
THF, dioxane, etc amides, such as DMF, DMA, etc, are  
mentioned. Among others, DMF, DMA or THF is used  
advantageously, because concentration is unnecessary in  
pre-stage of the next reaction step. The reaction  
25      temperature is about 0 to 50°C, preferably about 20 to  
40°C. The reaction time is about 3 to 15 hours,  
preferably about 5 to 10 hours. This reaction is  
preferably conducted under a normal pressure.

30      Alternatively, in order to decrease the occurrence  
of di-ketopiperazine at the reduction reaction, it is  
preferable to subject de-Z peptide (a) to a protonation  
reaction before the catalytic reduction. At the  
protonation reaction, an acid is added to the reaction  
35      system. As the acid, mention is made of inorganic acid  
or organic acid, preferably hydrochloric acid, sulfuric  
acid, p-toluenesulfonic acid. Among them, p-

toluenesulfonic acid is more preferable. The amount of the acid is preferably about 0.8 to 1.5 times (mole/mole), more preferably 1 to 1.1 times (mole/mole), that of de-Z peptide (a).

5       The HBr/AcOH treatment is carried out by reacting Peptide (a) with HBr together with a saturated acetic acid without any solvent. The reaction temperature is about -10 to 30°C, preferably about 10 to 20°C. The reaction time is about 10 minutes to 2 hours,  
10      preferably about 30 minutes to one hour. The recovery of the objective peptide from the reaction mixture is carried out by recovering the emerged precipitate by adding ether, ethyl acetate and so on, and then by drying.

15      In the reaction of the introduction of Z-Ser group, the active ester method is used, i.e. converting the peptide to an active ester, and, the intramolecular dehydration reaction is successfully inhibited by optimization of reaction temperature. The active ester  
20      that can be used for the introduction of Z-Ser in the process of the invention includes various active esters that can be used in peptide synthesis, such as the esters with an active esterification agent, e.g. N-hydroxy-5-norbornene-2,3-dicarboximide (HONB), N-hydroxysuccinimide (HOSu), N-hydroxybenzotriazole (HOBT), etc. Particularly preferred is the HONB ester.

25      For preparing an active ester of Z-Ser-OH, Z-Ser-OH is reacted with an active esterification agent in a solvent such as ethers, e.g. diethylether, isopropylether, THF, dioxane, etc, amides, e.g. DMF, DMA, etc, acetonitrile, acid esters, e.g. methyl formate, methyl acetate, ethyl acetate, etc, at a temperature ranging from about -5 to 20°C, preferably about 0 to 5°C, for about 5 to 15 hours, preferably about 7 to 10 hours.

30      The reaction of de-Z peptide (a) an active ester

of and Z-Ser-OH is carried out in an inert solvent. The solvent used in the reduction reaction in the former step may be used. Among others, amides, e.g. DMF, DMA, are preferable. The reaction is carried out 5 at a lower temperature such as a temperature ranging from -10 to 10°C, preferably about -5 to 5°C, for about 5 to 20 hours, preferably about 7 to 12 hours.

3. Method for producing Peptide (c) from Peptide (b):  
Peptide (c), Z-Trp-Ser-R<sup>2</sup>-R<sup>3</sup>-OR<sup>9</sup> (SEQ ID NO: 1)  
10 which is shown in Figure 1, is produced by subjecting a peptide obtained by de-Z reaction of Peptide (b) (de-Z peptide (b)) with a peptide, Z-Trp-OH to a condensation reaction.

The de-Z reaction is carried out by a catalytic 15 reduction by employing a catalyst such as Pd, Pd-C, or by a treatment using HBr/AcOH treatment. The catalytic reduction and HBr/AcOH treatment is carried out by a manner similar to those mentioned in the method for producing Peptide (b) from Peptide (a).

20 Introduction of Z-Trp into the peptide obtained by de-Z reaction of Peptide (b) can be carried out by reacting Peptide (b) with an active ester of Z-Trp-OH, which is previously produced by reacting Z-Trp-OH with an active esterification agent, e.g. HONB, HOBr, HOSu, 25 in the presence of a condensation agent, e.g. DCC, EDA, etc. Also, Peptide (b) and Z-Trp-OH can be condensed by reacting both using a condensation agent in the presence of an active ester.

As the active ester, HONB is preferable, and as 30 the condensation agent, DCC is preferable. The method for producing active ester of Z-Trp-OH can be a similar manner as above.

The reaction of Peptide (b) with the active ester 35 of Z-Trp-OH in the presence of a condensation agent is carried out at a temperature ranging from about 0 to 20°C, preferably about 5 to 10°C for about 5 to 20

hours, preferable about 7 to 10 hours.

4. Method for producing Peptide (e) from Peptide (c) and Peptide (d):

Peptide (d), Z-5-oxo-Pro-R<sup>1</sup>-OH, can be produced by  
5 the method of Hatanaka et al. [Takeda Research Report,  
35, 16 (1976); Biochemical and Biophysical Research  
Communications, 60, 1345 (1974)], or a similar method  
as above.

Peptide (e), Z-5-oxo-Pro-R<sup>1</sup>-Trp-Ser-R<sup>2</sup>-R<sup>3</sup>-OR<sup>9</sup> (SEQ  
10 ID NO:2), is produced by a condensation reaction of  
Peptide (c) with Peptide (d). In the condensation,  
attention must be paid to the isomerization of the His  
residue but any of the known anti-isomerizing  
procedures available for the fragment condensation of  
15 peptides can be utilized. A typical procedure for  
suppressing this isomerization consists in the use of  
an anti-isomerizing agent in addition to a condensing  
agent. The condensing agent may for example be DCC or  
EDA and the anti-isomerizing agent may for example be  
20 HONB, HOSu, HOBT, (HOSu), or the like. These two kinds  
of agents can be used in any desired combination.  
Typical combinations are DCC-HONB, DCC-HOSu, DCC-HOBT,  
and EDA-HOSu, among others. Particularly preferred is  
25 DCC-HONB. While the reaction temperature is a major  
factor in the control of isomerization, the preferred  
reaction temperature is about 0 to 20°C, preferably  
about 5 to 15°C for 30 minutes to 100 hours, preferably  
about 50 to 80 hours. In the reaction, as a solvent,  
use is made of amides, e.g. DMF, DMA, etc, ethers, e.g.  
30 2-methylpyrrolidone, THF, dioxane, etc.

5. Method for producing Peptide (IV) from Peptide (e):

Elimination of Z from Peptide (e), Z-5-oxo-Pro-R<sup>1</sup>-  
Trp-Ser-R<sup>2</sup>-R<sup>3</sup>-OR<sup>9</sup> (SEQ ID NO: 2), gives Peptide (IV).  
35 The de-Z reaction is carried out with methods such as  
catalytic reduction with a catalyst, e.g. Pd, Pd-C, or

the like, or HBr/AcOH treatment.

In the catalytic reduction, as a solvent, use is made of amides, e.g. DMF, DMA, etc, ethers, e.g. 2-methylpyrrolidone, THF, dioxane, etc, or t-butanol, at 5 a temperature ranging from about 0 to 50°C, preferably about 25 to 40°C, for about 1 to 10 hours, preferably about 3 to 6 hours.

The HBr/AcOH treatment is carried by a method similar to those mentioned in the reaction from Peptide 10 (a) to Peptide (b).

6. Method for producing Peptide (II) from Peptide (IV):

Peptide (II) can be produced by hydrolyzing Peptide (IV), and if necessary, neutralizing the 15 reaction mixture.

This hydrolysis reaction is preferably carried out in a mixture of water and an alcohol at a low temperature. The alcohol that can be used includes methanol, ethanol, propanol, n-butanol, etc. and the 20 proportion of the alcohol in the water-alcohol mixture is about 1 to 30% (v/v), preferably about 1 to 10% (v/v). The larger the proportion of the alcohol, the lower is the velocity of hydrolysis reaction and, at the same time, the rates of isomerization of His<sup>2</sup> and 25 Ser<sup>4</sup> are significantly increased (when R<sup>1</sup> is His).

These isomers cannot be efficiently removed even by the column chromatographic system used in purification, thus detracting from the quality of the final product, Peptide (I).

30 The reaction solvent may contain the solvent carried over from the upstream stage, viz. DMF, THF, or the like, but its proportion should not be large enough to retard the reaction in any appreciable measure, i.e. preferably about 1 to 20% (v/v), preferably about 5 to 35 10% (v/v).

The hydrolysis is carried out in the presence of

alkali. As the alkali, mention is made of sodium hydroxide, potassium hydroxide, calcium hydroxide, barium hydroxide. The reaction speed of hydrolysis and isomerization of His at 2-position and Ser at 4-  
5 position depend upon the amount of alkali and its concentration in the solution. The amount of the alkali is preferably about 2.5 to 2 times mole/mole per Peptide (IV), preferably about 3 to 4 times mole/mole. In particular, the concentration of alkali in the  
10 reaction system at the initial time of the reaction is preferably about 0.05 to 0.3 mole/liter, more preferably about 0.1 to 0.2 mole/liter. The reaction temperature should be maintained at about -10 to 10°C, preferably about -5 to 5°C, up till completion of the  
15 after-treatment, namely neutralization. In order to keep the reaction temperature constant, the reaction system is preferably agitated. This reaction generally goes to completion in 1.5 to 3 hours. In order that the objectionable isomerization may be minimized, the  
20 neutralization procedure is preferably carried out immediately following the reaction. This neutralization is carried out at a temperature ranging from -5 to 5°C, preferably -2 to 2°C using an acid (e.g. hydrochloric acid, sulfuric acid, etc.).  
25 The peptide (II) can be crystallized by the following method:

Thus, the gels formed in the neutralization of the reaction mixture following hydrolysis of (IV) are dissolved by heating and then allowed to cool gradually  
30 to let Peptide (II) crystallize out. The dissolution by heating is carried out at a temperature ranging from about 60 to 80°C, preferably about 65 to 75°C under stirring. This crystallization can be facilitated by adding seed crystals in the cooling phase. As to the  
35 timing of addition, seed crystals can be added at any time during the phase where the added seed crystals

will not dissolve in the solution and the hot solution will not give rise to gels again. Preferred is the phase where the temperature of the solution is about 35 to 45°C. The gradual cooling is carried out for about 5 1 to 3 hours, at a temperature ranging from 15 to 30°C.

In order to complete the crystallization, it is preferable to subject the product to aging. The time for aging for obtaining crystals of Peptide (II), which have excellent properties with a high yield, is about 10 30 to 150 hours, preferably about 60 to 100 hours. The temperature of aging is preferably about 10 to 35°C, more preferably about 10 to 30°C, still more preferably about 15 to 25°C.

As the concentration of Peptide (II) in the 15 solution at the initial time of aging, about 0.01 to 0.05 mole/liter is provided, preferably about 0.02 to 0.04 mole/liter.

In the course of aging, it is preferable to stir 20 the Peptide (II)-containing solution intermittently, for shortening the aging time and/or obtaining a high yield of the crystals. Thus it is preferable to stir the solution for about one minute at about 30 to 35rpm commencing five hours into the reaction. Thereafter, the solution is stirred for about one minute at about 25 30 to 35rpm about every five hours until the aging process is 2/3 completed. Thereafter, the solution is stirred for about one minute at about 30 to 35rpm about every 0.5 hours until the final step of aging.

More concretely, e.g., the aging time is 60 hours, 30 the solution is stirred at 33 rpm for 1 minute every 5 hours beginning 5 hours into the reaction, until 40 hours. Thereafter, the solution is stirred at 33 rpm for 1 minute every 0.5 hour from 40 hours after the starting of the aging to the last step.

35 By the above crystallization procedure for Peptide (II), the time-consuming operations for removal of

contaminants that would affect the final product quality, such as the His isomer by-produced in the fragment condensation reaction of Peptide (c) to Peptide (e) and hydrolysis reaction of Peptide (IV) to Peptide (II) and the Ser isomer by-produced in the hydrolysis reaction of Peptide (IV) to Peptide (II), as well as the procedure for isolation of Peptide (IV), can all be omitted.

The Peptide (II) can be used for the next reaction in the form of a salt with an alkali metal, e.g. Li, Na, K, Ca, Ba, etc., or an organic base, e.g. triethylamine, cyclohexylamine, dicyclohexylamine, either as isolated by a known method such as crystallization or in the solution form as such.

15 7. Production of Peptide (III):

Peptide (III) or a salt thereof can be produced by the method of Fujino et al. Archives of Biochemistry and Biophysics, 154, 488 (1973); Chemical and Pharmaceutical Bulletin, 23, 229 (1975)] or any other known method for peptide synthesis.

Peptide (III) can be used for the next reaction in the form of a salt with, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, p-toluenesulfonic acid, trifluoroacetic acid, or methanesulfonic acid, either as isolated by a known separation procedure such as crystallization or in the solution form as such. In such cases, however, the amide bond-forming reaction has to be preceded by elimination of the base (acid) by neutralization with a base or treatment with an ion exchange resin.

30 8. Production of Peptide (I') from Peptide (II) and Peptide (III):

The condensation reaction of Peptide (II) with Peptide (III) to give Peptide (I') is carried out in a solvent which does not interfere with the reaction. The solvent that can be used includes N,N-

dimethylformamide (DMF), N,N-dimethylacetamide (DMA), N-methylpyrrolidone, dichloromethane, dichloroethane, tetrahydofuran, dioxane, etc. and these solvents can be used as a suitable mixture. Preferred are N,N-dimethylformamide and N,N-dimethylacetamide.

5 The proportion of Peptide (III) relative to Peptide (II) is about 0.5 to 2 molar equivalents, preferably about 1 to 1.5 molar equivalents.

10 The reaction temperature is generally about 0 to 40°C and preferably about 5 to 25°C. The range of the temperature is important for preventing isomerization of R<sup>3</sup>. The reaction time is generally about 30 to 60 hours and preferably about 40 to 50 hours.

15 In the condensation reaction of Peptide (c) with Peptide (d), attention must be paid to the isomerization of the group R<sup>3</sup> but any of the known anti-isomerizing procedures available for the fragment condensation of peptides can be utilized. A typical procedure for suppressing this isomerization (racemization) consists of the use of an anti-isomerizing agent in addition to a condensing agent. The condensing agent may for example be DCC or EDA and the anti-isomerizing agent may for example be HONB, HOSu, HOEt, or the like. These two kinds of agents can 20 be used in any desired combination. Typical combinations are DCC-HONB, DCC-HOSu, DCC-HOEt, and EDA-HOSu, among others. Particularly preferred is DCC-HONB.

25 The condensing agent is used at a ratio of one to 3 times (mole/mole) of Peptide (II), preferably one to two times (mole/mole). The amount of anti-isomerizing agent is one to 4 times (mole/mole) of Peptide (II), preferably 1.5 to 2.5 times (mole/mole). The initial concentration of Peptide (II) is about 0.05 to 0.2 mole/liter, preferably 0.08 to 1.5 mole/liter. Peptide 30 (III) is used in an amount of 0.8 to 2 times

(mole/mole), preferably 1 to 1.3 times (mole/mole), relative to Peptide (II).

9. Production of peptide (I) from Peptide (I'):

The deprotection reaction for removing the protective group from the Arg residue of Peptide (I') to give Peptide (I) can be carried out with an acid in a solvent that does not interfere with the reaction or in the absence of a solvent. The solvent that does not interfere with this deprotection reaction includes but is not limited to dichloromethane, dichloroethane, dioxane, and trifluoroacetic acid, and these solvents can be used as a suitable mixture.

The acid that can be used for this deprotection reaction includes but is not limited to C<sub>1-6</sub> alkanesulfonic acids, e.g. methanesulfonic acid, ethanesulfonic acid, etc., halogenosulfonic acids, e.g. chlorosulfonic acid, fluorosulfonic acid, bromosulfonic acid, etc, and Lewis acids, e.g. boron tris(trifluoroacetate), etc. Among these, C<sub>1-3</sub> alkanesulfonic acids are preferred and methanesulfonic acid is particularly preferred.

The proportion of the acid for use in this deprotection procedure is about 5 to 25 (w/w) times, preferably about 10 to 20 (w/w) times, based on the weight of Peptide (I').

The deprotection reaction temperature is generally about 0 to 20°C and preferably about 5 to 15°C.

The deprotection reaction time is generally about 2 to 8 hours and preferably about 4 to 6 hours.

This deprotection reaction is preferably carried out using methanesulfonic acid in the absence of a solvent.

In conducting this deprotection reaction, a radical scavenger (e.g. phenol, anisole, etc.) and/or an antioxidant (e.g. thioglycolic acid) may be added each in a suitable amount. Their amount may each be

about 0.8 to 2 (w/w) times, preferably about 0.05 to 2 (w/w) times, based on the above-mentioned reaction product.

When the deprotection reaction is conducted using  
5 a C<sub>1-6</sub> alkanesulfonic acid, the alkanesulfonic acid can  
be eliminated from the reaction mixture by, for  
example, the method comprising washing the reaction  
mixture with ether, dissolving water in the washes, and  
running the resulting solution on an anion exchange  
10 resin column. However, when this method is applied to  
commercial-scale production, the risk of using a large  
quantity of ether because the solubility of C<sub>1-6</sub>  
alkylsulfonic acid in ether is very low, the risk of  
abrupt evolution of heat at the mixing of a large  
15 quantity of the alkanesulfonic acid with water and upon  
running the solution on the ion exchange resin column,  
and the decomposition of the objective peptide due to  
the evolved heat make the method unsuitable from the  
standpoints of hardware required, workability, and  
20 safety.

As a commercially advantageous method free of the  
above problems, there is a technology for eliminating  
the alkanesulfonic acid from the reaction mixture by  
direct neutralization with a basic aqueous medium.  
25 However, in this neutralization process involving  
neutralization of a large quantity of the strong acid,  
evolution of an intense heat of neutralization is  
naturally expected despite the advantage of feasibility  
of large-scale treatment. In addition to the problem  
30 that a large quantity of the neutralized solution must  
be handled, the adverse influences on the quality of  
the end product compound due to cleavage of peptide  
bonds and isomerization of amino acid residues of the  
objective peptide in the basic aqueous medium are  
35 inevitable so that the method was considered to be  
lacking in common sense as far as the production of

peptides is concerned.

However, the inventors of the present invention explored into the methodology for absorbing the heat of neutralization evolved in this neutralization reaction 5 as well as the procedural aspect of the methodology and made efforts to optimize the reaction conditions. As a result, they discovered surprisingly that the objective compound of acceptable quality could be obtained in good yield and have established a production-scale 10 method for said neutralization. Thus, in accordance with the present invention, the reaction mixture is added dropwise to a cooled aqueous solution of an inorganic or organic base to neutralize the alkanesulfonic acid at a sustained low temperature. In 15 this mode of operation, isomerization of constituent amino acid residues of the objective peptide can be successfully inhibited and the objective compound be obtained either as solid or as oil.

The inorganic base that can be used for this 20 purpose includes sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate, potassium carbonate, calcium carbonate, etc., and the organic base that can be used includes pyridine, triethylamine, etc., although potassium carbonate is particularly 25 advantageous. When a carbonate is used as said base, copious foaming due to evolution of carbon dioxide gas is inevitable but this foaming can be controlled by adding an organic solvent such as ethyl acetate or benzene in a suitable proportion beforehand. The 30 amount of said inorganic or organic base need only be sufficient to neutralize the alkanesulfonic acid but is preferably about 1 to 1.3 equivalents relative to the alkanesulfonic acid.

In order that the isomerization of amino acid 35 residues and hydrolytic cleavage of the peptide chain may be inhibited and freezing of said aqueous solution

of inorganic or organic base may be prevented, the neutralization system temperature is preferably controlled at about -15 to 15°C, preferably about -5 to 5°C.

5       Upon neutralization, the objective compound usually separates out as solid or oil from the neutralization system and, therefore, can be recovered by a suitable known procedure such as filtration or decantation.

10      The objective compound separated from the neutralization system can be purified by per se known procedures. In the purification of a relatively small amount of the objective compound, liquid chromatography constitutes a method of choice. For the purification 15 of a large amount of the objective compound, there can be employed a combination of several known column chromatographic systems according to the ionic nature, polarity and other solution properties, aromaticity, and molecular weight of the particular compound.

20      The fractional purification technology preferred from industrial points of view includes a judicious combination of column chromatographic systems using a hyperporous resin such as Amberlite XAD-2 (Rohm & Haas Co., USA) or Diaion HP-20 (Mitsubishi Chemical, Japan), 25 carboxymethylcellulose (CMC, CM-23 (Whatman, USA)), an ion exchange resin such as Amberlite CG-50 (Rohm & Haas Co., USA), and a molecular sieve resin such as Sephadex LH-20 (Pharmacia Fine Chemicals, Sweden). This procedure is procedurally simple and safe and provides 30 for good reproducibility of both yield and quality, besides being economical.

35      An exemplary combination of column chromatographic systems may be a serial combination of Diaion HP-20 (mentioned above) (1st run) ~ CM-23 (mentioned above) ~ Diaion HP-20 (2nd run) ~ Sephadex LH-20 (mentioned above). When a solution containing a peptide is

subjected to concentration, it emerges vigorous foaming, and it is necessary to use a lyophilizing machine, or to add an anti-foaming agent. However, the combination of said column chromatography brings an  
5 advantageous method that the concentration procedure is omitted, the concentration being that on the effective fraction obtained in each column chromatography, especially the concentration of a large amount of the aqueous solution containing the effective fraction  
10 obtained by column chromatography of CM-23. Therefore, the combination of the above chromatography provides an industrially advantageous method in terms of operability and economically, as well as high quality which depend upon restraining decomposition of peptides  
15 due to concentration.

Diaion HP-20 (1st run) column chromatography has for its primary object to eliminate inorganic contaminants, as well as the radical scavenger added in the deprotection step and its reaction product, the  
20 antioxidant optionally added, and isomers of the objective compound as produced in minor amounts, from the solid or oil containing the crude objective compound as separated from the reaction mixture after the deprotection reaction. Referring, further, to this  
25 Diaion HP-20 (1st run) column chromatography, Diaion HP-20 is used in a proportion of about 20 to 40 (v/w) times, preferably about 25 to 35 times, relative to the objective compound. Elution of the objective compound and contaminants is generally carried out with an  
30 aqueous solution of acetone, methanol, or ethanol. In the following exemplary description, ethanol is used. First, the aqueous solution containing the objective compound is run on a Diaion HP-20 column and the column is irrigated serially with programmed amounts of sodium acetate/water preadjusted to pH 5 to 7 with acetic acid, ammonium acetate/water, and 10% (v/v) ethanol to  
35

elute related compounds. Then, the objective compound is eluted with 15% (v/v) ethanol and 35% (v/v) ethanol and the programmed fractions are pooled.

CM-23 column chromatography has for its primary object to eliminate byproducts ionically non-equivalent to the objective compound, and CM-23 is used in a proportion of generally 35 to 60 times (v/w), preferably 40-55 times (v/w), relative to the objective compound. The solution available after distillation of ethanol from the programmed eluate from the Diaion HP-20 (1st run) column is run on a CM-23 column and the column is first rinsed with water. The objective compound is then eluted by serial elution with 0.015 M ammonium acetate/water and 0.03 M ammonium acetate/water and the programmed fractions are pooled.

Diaion HP-20 (2nd run) column chromatography has for its primary object to remove the ammonium acetate used in elution from the CM-23 column and concentrate the large amount of eluate. The programmed eluate available after CM-23 column chromatography (a large quantity of aqueous solution which would give copious foaming on concentration) can be applied directly, i.e. without prior concentration, to the Diaion HP-20 (2nd run) column. This Diaion HP-20 (2nd run) column is irrigated serially with sodium acetate/water preadjusted to pH about 5 to 7 with acetic acid, ammonium acetate/water, and water in the order mentioned. The objective compound is then eluted with 15% (v/v) ethanol and 35% (v/v) ethanol and the programmed fractions are pooled. The programmed eluate thus obtained from the Diaion HP-20 (2nd run) column (which has been concentrated to about 1/3 by volume of the programmed eluate from the CM-23 column) is concentrated under reduced pressure and the residue is run on a Sephadex LH-20 column.

Sephadex LH-20 column chromatography, which is the

final stage of the cascade, has for its object to eliminate pyrogenic substances, inorganic matter, and other trace contaminants. Sephadex LH-20 is used in a proportion of about 20 to 60 times (v/w), preferably 5 about 30 to 50 times (v/w), relative to the objective compound. The LH-20 column is developed with 0.005N acetic acid/H<sub>2</sub>O and the programmed fractions are pooled. Where necessary, this programmed eluate is concentrated, treated with active charcoal, membrane-10 filtered, and lyophilized to give the objective compound (acetate) as a final product.

Thus obtained Peptide (I) has a LHRH agonist activity, and can be used, for example, a similar manner as described in U.S. Patent No. 4,008,209.

15

#### Examples

The following examples are intended to describe the present invention merely in further detail and should by no means be construed as defining the scope 20 of the invention.

Reference Example 1. Production of Z-Tyr-D-Leu-OEt:  
Z-TyrOH•DCHA (58.8 g) was desalted with 1N-sulfuric acid in about 300 ml of ethyl acetate at 0 to 10°C. The organic layer was separated and dehydrated 25 over anhydrous sodium sulfate (Na<sub>2</sub>SO<sub>4</sub>). After the Na<sub>2</sub>SO<sub>4</sub> was filtered off, 24.3 g of D-Leu-OEt, 12.6 g of triethylamine, and 26.8 g of DCC were added to the filtrate and the mixture was stirred at about 5°C for about 2 hours and further at about 10°C for 5 hours.  
30 To this reaction mixture was added 60 ml of 1N-hydrochloric acid and the mixture was filtered. The filtrate was allowed to stand and the organic layer was washed with aqueous solution of NaCl and aqueous solution of NaHCO<sub>3</sub>, and the ethyl acetate was distilled off. To the residue was added isopropyl ether and the 35 resulting crystal crop was harvested by filtration,

recrystallized from ethyl acetate-isopropyl ether, and dried.

Yield 41.6 g (77%)

m.p. 116-118°C

5 Optical rotation  $[\alpha]_D^{25} = -3.4^\circ$  (c=1, DMF)

Reference Example 2. Production of Z-Ser-Tyr-D-Leu-OEt:

In about 300 ml of DMF were dissolved 40.5 g of Z-Tyr-D-Leu-OEt and 16.9 g of p-toluenesulfonic acid monohydrate, and hydrogenation was carried out in the presence of about 5 g of 5% Pd-C at 20 to 35°C. After completion of the reaction, the catalyst was filtered off.

15 Separately, 23.3 g of Z-Ser-OH and 19.2 g of HONB were dissolved in 300 ml of DMF followed by addition of 22.1 g of DCC and the mixture was stirred at 0 to 5°C for about 7 hours. To this mixture was added the above reduction reaction mixture. The mixture was cooled to about 0°C and 9 g of triethylamine was added dropwise. The mixture was then stirred at -5 to 5°C for about 10 20 hours and left standing at room temperature overnight.

The crystals which formed were filtered off and the filtrate was concentrated under reduced pressure. The residue was dissolved in ethyl acetate. This ethyl acetate solution was washed with 1N-HCl, aqueous 25 solution of NaCl, and aqueous solution of NaHCO<sub>3</sub>, in that order, and dehydrated over Na<sub>2</sub>SO<sub>4</sub>. After the Na<sub>2</sub>SO<sub>4</sub> was filtered off, the filtrate was concentrated under reduced pressure and diluted with isopropyl ether. The resulting crude crystal crop was harvested 30 by filtration, recrystallized from ethyl acetate, and dried.

Yield 37.6 g (77%)

m.p. 134-136°C

Optical rotation  $[\alpha]_D^{25} = -4.8^\circ$  (c=1, DMF)

35 Reference Example 3. Procution of Z-Trp-Ser-Tyr-D-Leu-OEt (SEQ ID NO: 7)

## (ETSTLE):

In 300 ml of DMF was dissolved 36.2 g of Z-Ser-Tyr-D-Leu-OEt, and hydrogenation was carried out in the presence of about 5 g of 5% Pd-C at 25 to 35°C. After 5 completion of the reaction, the catalyst was filtered off.

Separately, 21.4 g of Z-Trp-OH and 11.9 g of HONB were dissolved in about 300 ml of DMF followed by addition of 13.7 g of DCC and the mixture was stirred 10 at 5 to 10°C for about 7 hours. To this mixture was added the above reduction reaction mixture. The mixture was then stirred at 10 to 15°C for about 7 hours and left standing at room temperature overnight.

The crystals which formed were filtered off and 15 the filtrate was concentrated under reduced pressure. The residue was dissolved in ethyl acetate and this solution was washed with 1N-HCl, aqueous solution of NaCl, and aqueous solution of NaHCO<sub>3</sub>, in that order, and dehydrated over Na<sub>2</sub>SO<sub>4</sub>. After the Na<sub>2</sub>SO<sub>4</sub> was filtered 20 off, the filtrate was concentrated under reduced pressure and isopropyl ether was added to the residue. The resulting crude crystal crop was harvested by filtration, recrystallized from ethyl acetate-isopropyl ether, and dried.

25 Yield 41.3 g (85%)

Optical rotation  $[\alpha]_D^{25} = -10.0^\circ$  (c=1, EtOH)

Reference Example 4. Production of Z-5-oxo-Pro-His-Trp-Ser-Tyr-D-Leu-OEt (SEQ ID NO: 8):

30 In about 350 ml of DMF was dissolved 55.7 g of Z-Trp-Ser-Tyr-D-Leu-OEt (ZTSTLE), and hydrogenation was carried out in the presence of about 12 g of 5% Pd-C (wet) at about 30°C. After completion of the reaction, the catalyst was filtered off. To the filtrate thus 35 obtained were added 32.6 g of Z-5-oxo-Pro-His-OH·1.5H<sub>2</sub>O and 27.4 g of HONB, and after cooling to 2 to 8°C, 20.5

g of DCC was added. The mixture was stirred at about 8°C for about 60 hours.

This reaction mixture was further stirred at about 40°C for about 2 hours and then filtered and the 5 filtrate was concentrated under reduced pressure. To the residue was added about 1 L of ethyl acetate at about 60°C and the mixture was stirred at 20 to 25°C. The resulting crude crystals were collected by filtration, suspended in DMF (ca 230 ml)-ethyl acetate 10 (ca 530 ml), stirred, and recovered by filtration. The purified crystals (ZPGLE) thus obtained were not dried but directly submitted to the next reduction reaction.

Reference Example 5.     Synthesis of 5-oxo-Pro-His-Trp-Ser-Tyr-D-Leu-OEt (SEQ ID NO: 9):

The ZPGLE obtained in Reference Example 4 was dissolved in about 900 ml of DMF and hydrogenation was carried out in the presence of 15 g of 5% Pd-C (wet) at about 30°C. After completion of the reaction, the 20 catalyst was filtered off and the filtrate was concentrated to about 180 ml and subjected to the next hydrolysis reaction.

Reference Example 6.     Production of Z-Leu-ONP:

In 1.2 L of ethyl acetate was dissolved 125 g of 25 Z-Leu-OH as well as 65.5 g of p-nitrophenol, followed by dropwise addition of a solution of 107 g of DCC in ethyl acetate at 0 to 5°C, and the mixture was stirred at 10 to 25°C. After completion of the reaction, crystals were filtered off and the filtrate was 30 concentrated under reduced pressure. The residue was dissolved in ethanol and the crystals which formed were collected by filtration and dried in vacuo.

Yield 142 g (78%)

m.p. 92-94°C

35 Optical rotation  $[\alpha]_D^{25} = -42.5^\circ$  (c=1, CH<sub>3</sub>OH)

Reference Example 7.     Production of Z-Arg(MBS)-Pro-

**NHC<sub>2</sub>H<sub>5</sub>:**

In 400 ml of ethyl acetate was suspended 34.1 g of Z-Arg(MBS)-OH-DCHA, followed by addition of 57 ml of 1N-sulfuric acid at 0 to 10°C. The mixture was stirred and allowed to stand and the organic layer was washed with aqueous solution of sodium sulfate and concentrated under reduced pressure. On the other hand, 15.7 g of Z-Pro-NHC<sub>2</sub>H<sub>5</sub> was dissolved in 30 ml of N,N-dimethylacetamide and hydrogenation was carried out in the presence of 2.3 g of 5% Pd-C. After completion of the reaction, the catalyst was filtered off. In the filtrate was dissolved the Z-Arg(MBS)-OH-containing concentration residue as well as 9.4 g of HONB. To this solution was added a solution of 12.8 g of DCC in N,N-dimethylacetamide dropwise and the mixture was stirred at 10 to 20°C. After completion of the reaction, the crystals which formed were filtered off and the filtrate was concentrated under reduced pressure. The residue was dissolved in 450 ml of ethyl acetate and washed serially with 1N-HCl, aqueous solution of NaCl, and aqueous solution of NaHCO<sub>3</sub>, in that order. The ethyl acetate was distilled off under reduced pressure and the residue was treated with ethyl acetate-ethanol. The resulting crude crystalline crop was recrystallized from ethanol and dried in vacuo.

Yield 22.4 g (72%)

Optical rotation  $[\alpha]_D^{25} = -33.0^\circ$  (c=1, CH<sub>3</sub>OH)

Reference Example 8. Production of Z-Leu-Arg(MBS)-Pro-NHC<sub>2</sub>H<sub>5</sub>(ZLAP):

In 160 ml of DMF were dissolved 20.3 g of Z-Arg(MBS)-Pro-NHC<sub>2</sub>H<sub>5</sub> and 6.4 g of p-toluenesulfonic acid monohydrate, and hydrogenation was carried out in the presence of 2.3 g of 5% Pd-C. After completion of the reaction, the catalyst was filtered off and 3.4 g of triethylamine was added to the filtrate under ice-cooling. To this mixture was added 13.6 g of Z-Leu-ONP

and the mixture was stirred at 10 to 15°C. After completion of the reaction, the reaction mixture was concentrated under reduced pressure and the residue was dissolved in 120 ml of ethyl acetate. This solution  
5 was washed serially with diluted hydrochloric acid, aqueous solution of NaHCO<sub>3</sub>, and water. The ethyl acetate was then distilled off and the residue was applied to a silica gel column. The column was developed serially with ethyl acetate-isopropyl ether (1:1) and ethyl acetate-methanol (3:2) and the objective fractions were pooled and concentrated under reduced pressure. The residue was dissolved in ethyl acetate and treated with isopropyl ether and the resulting precipitate was recovered by filtration and  
10 dried in vacuo.  
15 Yield 22.2 g (92%)

Optical rotation  $[\alpha]_D^{25} = -39.0^\circ$  (c=1, CH<sub>3</sub>CH<sub>2</sub>OH)

Example 1. Production of 5-oxo-Pro-His-Trp-Ser-Tyr-  
20 D-Leu-OH (SEQ ID NO: 10) (PGLOH):

To the concentrate obtained in Reference Example 5 was added a solution of 8.3 g of sodium hydroxide in 1 L of water dropwise at -3 to 0°C and the mixture was stirred at about 0°C for about 2 hours. After the  
25 completion of reaction was confirmed, the reaction mixture was neutralized by adding 210 ml of 1N-hydrochloric acid dropwise at about 0°C. The crystals which formed were dissolved by heating and 1.5 g of active charcoal was added under heating. After  
30 stirring, the active charcoal was filtered off. The filtrate was allowed to cool and stirred at 15 to 25°C for 35 hours. The resulting crystals were collected by filtration and dried in vacuo at about 60°C.

Yield 39.9 g (59.2%, based on ZTSTLE obtained in  
35 Reference Example 3)  
Optical rotation  $[\alpha]_D^{25} = -21.5^\circ$  (c=0.5, DMF)

(1) Incidentally, whereas the objectionable isomerization at His in 2-position and Ser in 4-position after one hour of reaction using the above solvent system were 1.3% and 4.8%, respectively, at the reaction temperature of 20°C, the corresponding rates at the reaction temperature of 0°C were 0.2% and 0.44%, respectively.

(2) While the crystallization procedure according to the present invention effectively eliminates various structurally related compounds, examples of this elimination effect are shown below with focus on the products of His-isomerization and Ser-isomerization which are the most significant related compounds.

[Table 1]

	Reaction mixture	Crystals
	[D-His <sup>2</sup> ] compound	0.88% <sup>*)</sup>
	[D-Ser <sup>4</sup> ] compound	0.44%

\*) Inclusive of the [D-His<sup>2</sup>] isomer by-produced in the fragment condensation step of the method for the production of Peptide (e) from Peptide (c).

Example 2. Production of crystals of 5-oxo-Pro-His-Trp-Ser-Tyr-D-Leu-OH (SEQ ID NO: 10) (PGLOH):

To the concentrate obtained in Reference Example 5 was added a solution of 8.3 g of sodium hydroxide in 1 L of water dropwise at -3 to 0°C and the mixture was stirred at about 0°C for about 2 hours. After the completion of reaction was confirmed, the reaction mixture was neutralized by adding 210 ml of 1N-hydrochloric acid dropwise at about 0°C. The crystals which formed were dissolved by heating and 1.5 g of active charcoal was added under heating. After stirring, the active charcoal was filtered off. The filtrate was allowed to aging at 18 to 22°C for 80 hours. The resulting crystals were collected by filtration and dried in vacuo at about 60°C.

Yield 42.9 g (63.6%, based on ZTSTLE obtained in  
Reference Example 3)

Optical rotation  $[\alpha]_D^{25} = -21.8^\circ$  ( $c=0.5$ , DMF)

Example 3. Production of 5-oxo-Pro-His-Trp-Ser-Tyr-  
5 D-Leu-Leu-Arg(MBS)-Pro-NHC<sub>2</sub>H<sub>5</sub> (SEQ ID  
NO: 11) (briefly, MBSTAP):

In 350 ml of DMF was dissolved 35.6 g of ZLAP, and  
hydrogenation was carried out in the presence of 7.3 g  
of 5% Pd-C. Upon completion of the reaction, the  
10 catalyst was filtered off and 36.9 g of PGLOH and 16.2  
g of HONB were dissolved in the filtrate, followed by  
dropwise addition of a solution of 14 g of DCC in DMF  
at -4 to 8°C. The mixture was stirred at about 8°C for  
15 hours and further at about 20°C for about 30 hours.  
15 After completion of the reaction, the resulting  
crystals were filtered off and the filtrate was  
concentrated under reduced pressure and dissolved in  
about 200 ml of ethanol. Then, about 2.3 L of ethyl  
acetate was added and the resulting crystalline solid  
20 was recovered by filtration. This crude product was  
dissolved in about 220 ml of ethanol and about 900 ml  
of ethyl acetate was added. The resulting solid was  
recovered by filtration and washed with dichloromethane  
to provide MBSTAP as a wet product. This wet product  
25 was not dried but directly submitted to the next  
reaction for elimination of MBS. Assay by HPLC  
revealed that the yield of MBSTAP was 51.1 g (82%).

Example 4. Production of 5-oxo-Pro-His-Trp-Ser-Tyr-  
D-Leu-Leu-Arg-Pro-NHC<sub>2</sub>H<sub>5</sub>-CH<sub>3</sub>COOOH (SEQ ID  
30 NO:12) (briefly, TAP-144):

(1) Elimination of MBS

In 800 g of methanesulfonic acid was dissolved 60  
g of phenol, and the wet MBSTAP (equivalent to 51.1 g  
of MBSTAP) obtained in Example 1 was added to the  
35 solution under cooling. The mixture was then stirred  
at about 10°C for 5 hours.

Separately, 690 g of potassium carbonate was dissolved in 2 L of water and mixed with about 400 ml of ethyl acetate. This mixture was cooled to -2 to 0°C to provide an alkali solution. To this alkali solution 5 was added the above de-MBS reaction mixture dropwise at about 0°C. After completion of dropwise addition, the mixture was allowed to stand and a buffer solution (pH 4) (a mixture of ca 3 L of 0.1-N sodium acetate and ca. 58 ml of acetic acid) was added to the upper layer 10 (oil-ethyl acetate layer) to dissolve the oil. The mixture was then allowed to stand and the aqueous layer was washed with ethyl acetate.

The washed aqueous layer was adjusted to pH about 6 with 20% (w/w) solution of potassium carbonate and 15 the oil that had separated out was removed to provide an aqueous solution of TAP-144.

(2) Purification of crude TAP-144

The above aqueous solution of TAP-144 was applied 20 to a column (ca. 1.2 L) of DIAION™ HP-20. The column was then washed serially with about 2.5 L of 0.3 M sodium acetate/water (adjusted to pH 6.2 with acetic acid), about 3 L of 0.025 M ammonium acetate/water, and 4.3 L of 10% ethanol. Thereafter, 9.5 L of 15% ethanol and 9.5 L of 35% ethanol were passed in that order and 25 the objective fractions were pooled and concentrated under reduced pressure to remove the ethanol (S1-TAP).

This S1-TAP was applied to a column (ca. 1.7 L) of CM™-23 and after the column was washed with 2 L of water, the objective compound was eluted serially with 30 15 L of 0.015 M ammonium acetate/water and 15 L of 0.03 M ammonium acetate/water and the objective fractions were pooled (S2-TAP).

The S2-TAP obtained above was applied to a column 35 of DIAION™ HP-20 (ca. 0.7 L) and after the column was washed serially with about 2.1 L of 0.3 M sodium acetate (adjusted to pH 6.2 with acetic acid), 3.2 L of

0.01 M ammonium acetate/water, and 0.7 L of water, elution was carried out with 4.3 L of 15% ethanol and 5.4 L of 35% ethanol in that order. The objective fractions were pooled and concentrated under reduced pressure to about 200 ml. The residue was applied to a column of Sephadex<sup>TM</sup> LH-20 (ca. 10 L) and elution was carried out with 0.005N-acetic acid/H<sub>2</sub>O. The objective fractions were pooled and subjected to treatment with active charcoal, ultrafiltration, concentration, and lyophilization to provide 31.8 g (67.6%) of TAP-144. Content: 99.8% (HPLC, internal standard)  
Optical rotation  $[\alpha]_D^{20} = -39.0^\circ$  (c=1, 1% acetic acid)  
Absorbance: 57 (281 nm), 55 (289 nm)

15 Industrial Applicability

The process of the present invention has many advantages: namely i) the isomerization of His<sup>2</sup> and Ser<sup>4</sup> in the hydrolysis step is minimized, ii) the Peptide (II) can be obtained as quality crystals and the isomers by-produced in condensation and hydrolysis can be successfully removed, iii) the product compound available upon elimination of the alkoxybenzenesulfonyl group after treatment with an alkanesulfonic acid can be separated on a commercial scale, iv) the final compound can be purified on a commercial scale, v) the intermediate Peptide (b) can be obtained in good yield with the formation of byproducts being controlled, vi) the drying of intermediates Peptide (e) and Peptide (I') and the isolation of intermediate Peptide (IV) can be omitted. Thus, there is provided an industrial method for producing a peptide having LHRH agonistic activity.

## SEQUENCE LISTING:

SEQ ID NO: 1  
LENGTH: 4 amino acids  
5 TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
FEATURE:  
LOCATION: 1  
10 OTHER FEATURE: Xaa=Z-Trp  
LOCATION: 3  
OTHER FEATURE: Xaa=Tyr or Phe  
LOCATION: 4  
OTHER FEATURE: Xaa=optionslly substituted Gly-OR  
15 (R=a protecting group) or optionally substituted α-D-amino acid residue-OR  
(R=a protecting group)  
SEQUENCE:  
Xaa-Ser-Xaa-Xaa  
20 1  
  
SEQ ID NO: 2  
LENGTH: 6 amino acids  
TYPE: amino acid  
25 TOPOLOGY: linear  
MOLECULE TYPE: peptide  
FEATURE:  
LOCATION: 1  
OTHER FEATURE: Xaa=Z-5-oxo-Pro  
30 LOCATION: 2  
OTHER FEATURE: Xaa=His, Tyr, Trp or p-NH<sub>2</sub>-Phe  
LOCATION: 5  
OTHER FEATURE: Xaa=Tyr or Phe  
LOCATION: 6  
35 OTHER FEATURE: Xaa=optionslly substituted Gly-OR  
(R=a protective group) or optionally

substituted  $\alpha$ -D-amino acid residue-OR  
(R=a protective group)

SEQUENCE:

Xaa-Xaa-Trp-Ser-Xaa-Xaa

5 1 5

SEQ ID NO: 3

LENGTH: 6 amino acids

TYPE: amino acid

10 TOPOLOGY: linear

MOLECULE TYPE: peptide

FEATURE:

LOCATION: 1

OTHER FEATURE: Xaa=5-oxo-Pro

15 LOCATION: 2

OTHER FEATURE: Xaa=His, Tyr, Trp or p-NH<sub>2</sub>-Phe

LOCATION: 5

OTHER FEATURE: Xaa=Tyr or Phe

LOCATION: 6

20 OTHER FEATURE: Xaa=optionslly substituted Gly-OR  
(R=a protective group) or optionally  
substituted  $\alpha$ -D-amino acid residue-OR  
(R=a protective group)

SEQUENCE:

25 Xaa-Xaa-Trp-Ser-Xaa-Xaa

1 5

SEQ ID NO: 4

LENGTH: 6 amino acids

30 TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: peptide

FEATURE:

LOCATION: 1

35 OTHER FEATURE: Xaa=5-oxo-Pro

LOCATION: 2

OTHER FEATURE: Xaa=His, Tyr, Trp or p-NH<sub>2</sub>-Phe  
LOCATION: 5  
OTHER FEATURE: Xaa=Tyr or Phe  
LOCATION: 6  
5 OTHER FEATURE: Xaa=optionsally substituted Gly or  
optionally substituted α-D-amino acid  
residue  
SEQUENCE:  
Xaa-Xaa-Trp-Ser-Xaa-Xaa  
10 1 5  
  
SEQ ID NO: 5  
LENGTH: 9 amino acids  
TYPE: amino acid  
15 TOPOLOGY: linear  
MOLECULE TYPE: peptide  
FEATURE:  
LOCATION: 1  
OTHER FEATURE: Xaa=5-oxo-Pro  
20 LOCATION: 2  
OTHER FEATURE: Xaa=His, Tyr, Trp or p-NH<sub>2</sub>-Phe  
LOCATION: 5  
OTHER FEATURE: Xaa=Tyr or Phe  
LOCATION: 6  
25 OTHER FEATURE: Xaa=optionsally substituted Gly or  
optionally substituted α-D-amino acid  
residue  
LOCATION: 7  
OTHER FEATURE: Xaa=Leu, Ile, Nle  
30 LOCATION: 8  
OTHER FEATURE: Xaa=Arg which has been protected.  
LOCATION: 9  
OTHER FEATURE: Xaa=Pro-NHR (R= (1) Gly-NH-R',  
wherein R' represents a hydrogen atom  
35 or an alkyl group which may  
optionally be substituted with a

hydroxyl group or (2) NH-R", wherein  
R" represents a hydrogen atom, an  
alkyl group which may optionally be  
substituted with a hydroxyl group or  
an ureido group (-NH-CO-NH<sub>2</sub>))

5

## SEQUENCE:

Xaa-Xaa-Trp-Ser-Xaa-Xaa-Xaa-Xaa-Xaa

1

5

10

SEQ ID NO: 6

LENGTH: 9 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: peptide

15

## FEATURE:

LOCATION: 1

OTHER FEATURE: Xaa=5-oxo-Pro

LOCATION: 2

OTHER FEATURE: Xaa=His, Tyr, Trp or p-NH<sub>2</sub>-Phe

20

LOCATION: 3

OTHER FEATURE: Xaa=Tyr or Phe

LOCATION: 4

OTHER FEATURE: Xaa=optionsly substituted Gly or  
optionsly substituted α-D-amino acid  
residue

25

LOCATION: 7

OTHER FEATURE: Xaa=Leu, Ile, Nle

LOCATION: 9

30

OTHER FEATURE: Xaa=Pro-NHR (R= (1) Gly-NH-R',  
wherein R' represents a hydrogen atom  
or an alkyl group which may  
optionally be substituted with a  
hydroxyl group or (2) NH-R", wherein  
R" represents a hydrogen atom, an  
alkyl group which may optionally be  
substituted with a hydroxyl group or

35

an ureido group (-NH-CO-NH<sub>2</sub>))

SEQUENCE:

Xaa-Xaa-Trp-Ser-Xaa-Xaa-Xaa-Arg-Xaa

1 5

5

SEQ ID NO: 7

LENGTH: 4 amino acids

TYPE: amino acid

TOPOLOGY: linear

10 MOLECULE TYPE: peptide

FEATURE:

LOCATION: 1

OTHER FEATURE: Xaa=Z-Trp

LOCATION: 4

15 OTHER FEATURE: Xaa= D-Leu-O-C<sub>2</sub>H<sub>5</sub>,

SEQUENCE:

Xaa-Ser-Tyr-Xaa

1

20 SEQ ID NO: 8

LENGTH: 6 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: peptide

25 FEATURE:

LOCATION: 1

OTHER FEATURE: Xaa=Z-5-oxo-Pro

LOCATION: 6

OTHER FEATURE: Xaa= D-Leu-O-C<sub>2</sub>H<sub>5</sub>,

30 SEQUENCE:

Xaa-His-Trp-Ser-Tyr-Xaa

1 5

SEQ ID NO: 9

35 LENGTH: 6 amino acids

TYPE: amino acid

TOPOLOGY: linear  
MOLECULE TYPE: peptide

## FEATURE:

LOCATION: 1

5 OTHER FEATURE: Xaa=5-oxo-Pro

LOCATION: 6

OTHER FEATURE: Xaa= D-Leu-O-C<sub>2</sub>H<sub>5</sub>

## SEQUENCE:

Xaa-His-Trp-Ser-Tyr-Xaa

10 1 5

SEQ ID NO: 10

LENGTH: 6 amino acids

TYPE: amino acid

15 TOPOLOGY: linear

MOLECULE TYPE: peptide

## FEATURE:

LOCATION: 1

OTHER FEATURE: Xaa=5-oxo-Pro

20 SEQUENCE:

Xaa-His-Trp-Ser-Tyr-D-Leu

1 5

SEQ ID NO: 11

25 LENGTH: 9 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: peptide

## FEATURE:

30 LOCATION: 1

OTHER FEATURE: Xaa=5-oxo-Pro

LOCATION: 8

OTHER FEATURE: Xaa=Arg which has been protected by  
p-methoxybenzenesulfonyl

35 LOCATION: 9

OTHER FEATURE: Xaa=Pro-NH-C<sub>2</sub>H<sub>5</sub>

## SEQUENCE:

Xaa-His-Trp-Ser-Tyr-D-Leu-Leu-Xaa-Xaa  
1                  5

5      SEQ ID NO: 12

LENGTH: 9 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: peptide

10    FEATURE:

LOCATION: 1

OTHER FEATURE: Xaa=5-oxo-Pro

LOCATION: 9


OTHER FEATURE: Xaa=Pro-NH-C<sub>2</sub>H<sub>5</sub>

15    SEQUENCE:


Xaa-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Xaa  
1                  5

## CLAIMS

1. A method for producing a peptide of the formula:




wherein R<sup>1</sup> represents His, Tyr, Trp or p-NH<sub>2</sub>-Phe, R<sup>2</sup> represents Tyr or Phe, R<sup>3</sup> represents an optionally substituted Gly or an optionally substituted α-D-amino acid residue, R<sup>4</sup> represents Leu, Ile or Nle, R<sup>6</sup> represents (1) Gly-NH-R<sup>7</sup>, wherein R<sup>7</sup> represents a hydrogen atom or an alkyl group which may optionally be substituted with a hydroxyl group or (2) NH-R<sup>8</sup>, wherein R<sup>8</sup> represents a hydrogen atom, an alkyl group which may optionally be substituted with a hydroxyl group or an ureido group (-NH-CO-NH<sub>2</sub>), or its salts, which comprises reacting a peptide of the formula:



wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> have the same meanings as defined above or its salts, with a peptide of the formula:



wherein R<sup>4</sup> and R<sup>6</sup> have the same meaning as defined above and R<sup>5</sup> represents Arg which has been protected, or its salts, to produce a peptide of the formula:



wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> have the same meanings as defined above or its salt, and then subjecting thus obtained peptide (I') to a de-protecting group reaction.

2. A method according to Claim 1, wherein R<sup>1</sup> is His, R<sup>2</sup> is Tyr, R<sup>3</sup> is Gly, D-Leu, D-Trp, D-Val which may be substituted with C<sub>1-4</sub> alkyl, D-Ser, D-Ala which may be substituted with C<sub>1-4</sub> alkoxy, with naphthyl or with 2-methylindolyl, or D-His which may be substituted with C<sub>7-10</sub> aralkyl, R<sup>4</sup> is Leu, R<sup>5</sup> is Arg which is protected with a group selected from the group consisting of a C<sub>1-6</sub> alkoxybenzenesulfonyl group, tri-C<sub>1-6</sub>

alkylbenzenesulfonyl group and a nitro group, R<sup>6</sup> is a group of the formula: NH-R<sup>8'</sup>, wherein R<sup>8'</sup> is a hydrogen atom or an alkyl group which may optionally be substituted with hydroxyl.

3. A method according to Claim 1, wherein R<sup>1</sup> is His, R<sup>2</sup> is Tyr, R<sup>3</sup> is D-Leu, R<sup>4</sup> is Leu, R<sup>5</sup> is Arg which is protected with a C<sub>1-6</sub> alkoxybenzenesulfonyl group, R<sup>6</sup> is a group of the formula: NH-R<sup>8''</sup>, wherein R<sup>8''</sup> is a C<sub>1-3</sub> alkyl group which may optionally be substituted with hydroxyl.

4. A method according to Claim 1, wherein the reaction of the peptide (II) or its salts with the peptide (III) or its salts is carried out at a temperature ranging from about 0 to 40°C for about 30 to 60 hours.


5. A method according to Claim 1, wherein an acid is used in the de-protecting group reaction.

6. A method according to Claim 5, wherein the acid is C<sub>1-6</sub> alkylsulfonic acid.

7. A method according to Claim 5, wherein the acid is used at a ratio of about 5 to 25 times (weight) of the peptide (I').

8. A method for recovering and purifying the peptide (I) as defined in the above item 1, which comprises subjecting the reaction mixture containing an emerged oily product of a free form to a purification of column chromatography, the reaction mixture being obtained by the reaction of de-protecting group reaction of the Peptide (I') under the existence of an acid and then neutralized with a base.

9. A peptide of the formula:



wherein R<sup>1</sup> is His, Tyr, Trp or p-NH<sub>2</sub>-Phe, R<sup>2</sup> is Tyr or Phe, R<sup>3</sup> is optionally substituted Gly or an optionally substituted α-D-amino acid residue and R<sup>9</sup> is a protecting group, or its salt.


10. A peptide according to Claim 9, wherein R<sup>1</sup> is His, R<sup>2</sup> is Tyr, R<sup>3</sup> is Gly, D-Leu, D-Trp, D-Val which may be substituted with C<sub>1-4</sub> alkyl, D-Ser, D-Ala which may be substituted with C<sub>1-4</sub> alkoxy, D-Ala with naphthyl or with 2-methylindolyl or D-His which may be substituted with C<sub>7-10</sub> aralkyl, R<sup>9</sup> is C<sub>1-6</sub> alkyl, C<sub>6-10</sub> aryl or C<sub>7-12</sub> aralkyl, or its salt.

11. A peptide according to Claim 9, wherein R<sup>1</sup> is His, R<sup>2</sup> is Tyr, R<sup>3</sup> is D-Leu, R<sup>9</sup> is C<sub>1-6</sub> alkyl, or its salt.

12. A method for producing a peptide of the formula:




wherein R<sup>1</sup> is His, Tyr, Trp or p-NH<sub>2</sub>-Phe, R<sup>2</sup> is Tyr or Phe, R<sup>3</sup> is optionally substituted Gly or an optionally substituted α-D-amino acid residue, or its salt, which comprises hydrolyzing a peptide of the formula:




wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> have the same meanings as defined above, R<sup>9</sup> is a protecting group, or its salt.

13. A crystal of a peptide of the formula:



wherein R<sup>1</sup> is His, Tyr, Trp or p-NH<sub>2</sub>-Phe, R<sup>2</sup> is Tyr or Phe, R<sup>3</sup> is optionally substituted Gly or an optionally substituted α-D-amino acid residue, or its salt.

14. A method for producing a crystal of a peptide of the formula:




wherein R<sup>1</sup> is His, Tyr, trp or p-NH<sub>2</sub>-Phe, R<sup>2</sup> is Tyr or Phe, R<sup>3</sup> is optionally substituted Gly or an optionally substituted α-D-amino acid residue, or its salt, which comprises subjecting a solution of the peptide (II) or its salt to aging, and

15. A method according to Claim 14, wherein the solution of the peptide (II) or its salt with the concentration of about 0.01 to 0.05 mole/liter is subjected to aging at a temperature ranging from about

**10 to 70°C for about 10 to 70 hours.**

Figure 1



## INTERNATIONAL SEARCH REPORT

International Application No PCT/JP 97/02097
---

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C07K7/23 C07K1/02 C07K1/06
---

According to International Patent Classification (IPC) or to both national classification and IPC
---

B. FIELDS SEARCHED
--------------------

Minimum documentation searched (classification system followed by classification symbols) IPC 6 C07K
---

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
---

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
--

C. DOCUMENTS CONSIDERED TO BE RELEVANT
--

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 033 976 A (TAKEDA CHEMICAL INDUSTRIES LTD) 19 August 1981 see page 5, paragraph 1 - paragraph 2; example 4 ---	1-8
X	US 3 997 516 A (NISHIMURA OSAMU) 14 December 1976 cited in the application see examples 4,5 ---	1,5-8
A	US 3 855 198 A (SARANTAKIS D) 17 December 1974 see the whole document ---	1-8 -/-

<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.
--

<input checked="" type="checkbox"/> Patent family members are listed in annex.
--

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the International filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the International filing date but later than the priority date claimed

- "T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "Z" document member of the same patent family

2

Date of the actual completion of the international search  27 October 1997	Date of mailing of the international search report  14/11/1997
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patenttaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3016	Authorized officer  Cervigni, S

## INTERNATIONAL SEARCH REPORT

International Application No PCT/JP 97/02097
---

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE WPI            Section Ch, Week 7803            Derwent Publications Ltd., London, GB;            Class B04, AN 78-04222a            XP002039369            &amp; CA 1 023 350 A (AMERICAN HOME PROD) , 17            December 1974            see abstract</p> <p>---</p>	9
Y	<p>DATABASE WPI            Section Ch, Week 7503            Derwent Publications Ltd., London, GB;            Class B04, AN 75-04690w            XP002039370            &amp; JP 49 100 081 A (TAKEDA CHEM IND LTD) ,            September 1974            see abstract</p> <p>---</p>	9-12
Y	<p>EP 0 328 090 A (ABBOTT LAB) 16 August 1989            * see example 2, paragraph (g) and (h) *            see page 14</p> <p>-----</p>	9-12

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No	
PCT/JP 97/02097	

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0033976 A	19-08-81	JP 1608226 C JP 2028599 B JP 57114565 A JP 1507807 C JP 56113759 A JP 63058822 B JP 1608225 C JP 57077652 A JP 63046759 B CA 1177826 A DK 58081 A US 4368150 A US 4487726 A CA 1187512 C	28-06-91 25-06-90 16-07-82 26-07-89 07-09-81 17-11-88 28-06-91 15-05-82 19-09-88 13-11-84 13-08-81 11-01-83 11-12-84 21-05-85
US 3997516 A	14-12-76	JP 1222303 C JP 51100030 A JP 58055134 B JP 1153908 C JP 51006926 A JP 57047905 B CA 1045116 A CH 611878 A DE 2528935 A FR 2277078 A GB 1509928 A NL 7507980 A,B, NL 8801085 A,C	15-08-84 03-09-76 08-12-83 30-06-83 20-01-76 13-10-82 26-12-78 29-06-79 22-01-76 30-01-76 04-05-78 06-01-76 01-08-88
US 3855198 A	17-12-74	DE 2347151 A	04-04-74
EP 0328090 A	16-08-89	DE 68928278 D EP 0400065 A MX 9202974 A WO 8907450 A US 5300492 A	02-10-97 05-12-90 01-07-92 24-08-89 05-04-94